

# **A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery**

## **Authors**


Hubert J. Sijben<sup>1</sup>, Julie J.E. van den Berg<sup>1</sup>, Jeremy D. Broekhuis<sup>1</sup>, Adriaan P. IJzerman<sup>1</sup> and Laura H. Heitman<sup>1,2,\*</sup>

<sup>1</sup> Division of Drug Discovery and Safety, LACDR, Leiden University, The Netherlands

<sup>2</sup> Oncode Institute, Leiden, The Netherlands


**\* Corresponding author:** Division of Drug Discovery and Safety, LACDR, Leiden University, P.O. Box 9502, 2300RA Leiden, The Netherlands. Tel.: +31 71 527 4558. Email: [l.h.heitman@lacdr.leidenuniv.nl](mailto:l.h.heitman@lacdr.leidenuniv.nl)

## Supplementary Material




**Figure S1.** Representative vehicle-corrected xCELLigence traces of GPCR antagonists in three cell lines. **(a)** Pretreatment of U2OS-DAT cells with 1  $\mu\text{M}$  antagonist for 1 h. **(b)** Stimulation of non-transfected U2OS cells with 316 nM dopamine after pretreatment with vehicle, 1  $\mu\text{M}$  SCH23390 or raclopride for 1 h. **(c)** Pretreatment of Jumpln-DAT cells in the


presence of 1  $\mu\text{g/ml}$  dox (+dox) with 1  $\mu\text{M}$  antagonist for 1 h. Data are shown as the mean of a representative graph of at least three separate experiments each performed in duplicate.



**Figure S2.** Representative vehicle-corrected xCELLigence traces of DAT inhibitors in two cell lines. **(a)** Pretreatment of U2OS-DAT cells with 10  $\mu$ M GBR12909 for 1 h. **(b)** Pretreatment of JumptIn-DAT cells in the presence of 1  $\mu$ g/ml dox (+dox) with 10  $\mu$ M GBR12909 or cocaine for 1 h. Data are shown as the mean of a representative graph of at least three separate experiments performed with 16 replicates.



**Figure S3.** Dose-response curves of dopamine on (a) U2OS-DAT, U2OS-mock and (b) JumpIn-DAT cells with or without 1  $\mu$ g/ml dox ( $\pm$ dox). Data are shown as the net AUC of the first 120 minutes (U2OS) or 30 minutes (JumpIn-DAT) after stimulation normalized to the cell response of 31.6  $\mu$ M (U2OS) or 316  $\mu$ M (JumpIn-DAT) dopamine. U2OS-DAT and dox-treated JumpIn-DAT cells were pretreated with 10  $\mu$ M GBR12909, 10  $\mu$ M cocaine (dox-treated JumpIn-DAT only) or vehicle. Data were fitted with non-linear regression to a sigmoidal dose-response curve with a variable slope. Data are shown as mean  $\pm$  SEM of three to nine separate experiments each performed in duplicate.



**Figure S4.** Radioligand binding experiments. **(a)** Binding of ~10 nM [<sup>3</sup>H]WIN35,428 to 40 μg U2OS-mock or U2OS-DAT membranes. Total binding and non-specific binding were determined in the absence or presence of 100 μM GBR12909, respectively. Data are shown as mean ± SD of two experiments each performed in triplicate. **(b)** Representative saturation binding curve of [<sup>3</sup>H]SCH23390 to D<sub>1</sub>R on non-transfected U2OS membranes. Total binding (●) and non-specific binding (○) were determined in the absence or presence of 10 μM (+)-butaclamol, respectively. Specific binding (■) was obtained by linear subtraction of non-specific binding from total binding. Data is shown as the mean of a representative graph of three separate experiments each performed in triplicate. **(c)** Binding of ~0.8 nM [<sup>3</sup>H]SCH23390 to 40 μg U2OS-DAT or non-transfected U2OS membranes. Total binding and non-specific binding

were determined in the absence or presence of 10  $\mu$ M (+)-butaclamol. Data are shown as mean  $\pm$  SD of two experiments each performed in triplicate. DPM = disintegrations per minute.

**Table S1.**

Apparent potency values ( $pEC_{50}$ ) of dopamine and pseudo-Hill slopes of the concentration-effect curves on U2OS-mock, U2OS-DAT or JumpIn-DAT ( $\pm$ dox) cells in TRACT assays using a non-linear regression analysis model with a variable slope. Values are reported as the mean  $\pm$  SEM of three to nine individual experiments performed in duplicate, unless stated otherwise. Significant difference between two mean potency values was determined by unpaired two-tailed Student's t-test. <sup>†††</sup>  $p < 0.001$  (compared to JumpIn-DAT (-dox)/dopamine); <sup>‡</sup>  $p < 0.05$  (compared to JumpIn-DAT (+dox)/dopamine); <sup>##</sup>  $p < 0.01$  (compared to U2OS-DAT/dopamine); <sup>\*\*\*</sup>  $p < 0.001$  (compared to JumpIn-DAT/dopamine). Comparison of multiple mean values to vehicle control was done using a one-way ANOVA with Dunnett's post-hoc test. <sup>&&&</sup>  $p < 0.001$  (compared to JumpIn-DAT (+dox)/dopamine).

Cell line	Compound	$pEC_{50} \pm SEM$	slope $\pm SEM$	<i>n</i>
U2OS-mock	Dopamine	5.4 (5.2, 5.5) <sup>a</sup>	0.9 (1.0, 0.8) <sup>a</sup>	2
U2OS-DAT	Dopamine	4.7 $\pm$ 0.2	1.5 $\pm$ 0.1	5
	Dopamine + 10 $\mu$ M GBR12909	5.0 $\pm$ 0.4	0.9 $\pm$ 0.1 <sup>##</sup>	4
JumpIn-DAT -dox	Dopamine	5.1 $\pm$ 0.1	0.8 $\pm$ 0.1	7
	Dopamine	4.5 $\pm$ 0.0 <sup>†††</sup>	1.5 $\pm$ 0.1 <sup>***</sup>	9
JumpIn-DAT +dox	Dopamine + 10 $\mu$ M GBR12909	4.5 $\pm$ 0.1	0.8 $\pm$ 0.1 <sup>&amp;&amp;&amp;</sup>	4
	Dopamine + 10 $\mu$ M cocaine	4.7 $\pm$ 0.1	0.7 $\pm$ 0.1 <sup>&amp;&amp;&amp;</sup>	4

<sup>a</sup> Mean (individual values) of two individual experiments each performed in duplicate